Masking update: As of November 18, 2025, masks are required in patient care areas, patient rooms and waiting rooms. 

Community-onset Bacterial Meningitis

An Antimicrobial Stewardship clinical summary.
Antimicrobial Stewardship menu

These materials are intended for general clinical education and guidance. They are not a substitute for a clinician’s knowledge, skill or judgment in treating patients.

Note: Urgent Infectious Disease consultation strongly advised.

Background

Meningitis is inflammation of the meninges and is a medical emergency.

Initial assessment

  • Empiric antibiotic therapy should begin as soon as possible in suspected cases; time to antibiotics should not exceed one hour.
  • When feasible, perform a lumbar puncture and send for cell count, glucose, protein, culture and BioFire EM multiplex PCR.
  • A head CT before lumbar puncture (LP) is recommended if any of the following are present:
    • focal neurologic deficits
    • new-onset seizures
    • severely altered mental status (Glasgow Coma Scale score < 10)
    • A severely immunocompromised state
  • In patients without these findings, head CT before LP is not recommended and is associated with poorer outcomes.
  • If LP is delayed (for example, for a head CT), start empiric therapy immediately after obtaining blood cultures, even if the diagnosis has not been confirmed.

Common pathogens

  • S. pneumoniae
  • N. meningitidis
  • L. monocytogenes
  • H. influenzae

Empiric therapy (first-line)

No known allergies:

  • Ceftriaxone 2 g IV q12h

AND

  • Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h

AND

  • Dexamethasone 10 mg IV q6h for four days* (start immediately before, with, or up to four hours after the first antibiotic dose)

Consider also:

  • Ampicillin 2 g IV q6h (if age ≥ 50, pregnant or immunocompromised)
  • Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present

Alternative regimens for allergy to first-line regimen

Penicillin or amoxicillin allergy (unknown reaction, intolerance and/or type 1 hypersensitivity):

  • Ceftriaxone 2 g IV q12h

AND

  • Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h

AND

  • Dexamethasone 10 mg IV q6h for four days* (start immediately before, with or up to four hours after the first dose of antibiotics)

Consider also:

  • TMP-SMX 5 mg/kg (based on TMP component) IV q6h in place of ampicillin (if age ≥ 50, pregnant or immunocompromised)
  • Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present

Severe systemic or cutaneous reaction (unable to use any beta-lactem):

  • Moxifloxacin 400 mg IV q24h (in place of ceftriaxone)

AND

  • Vancomycin 25 mg/kg IV (loading dose once), then 15 mg/kg IV q12h

AND

  • Dexamethasone 10 mg IV q6h for four days* (start immediately before, with or up to four hours after the first dose of antibiotics)

Consider also:

  • TMP-SMX 5 mg/kg (based on TMP component) IV q6h in place of ampicillin (if age ≥ 50, pregnant or immunocompromised)
  • Acyclovir 10 mg/kg IV q8h if clinical features of encephalitis are present

Targeted therapy for common pathogens

OrganismAntibiotic susceptibilityTargeted therapyDuration
S. pneumoniaePenicillin-susceptiblePenicillin G 4 million units IV q4h10 days
Penicillin-resistant AND ceftriaxone-susceptibleCeftriaxone 2 g IV q12h
Penicillin-resistant AND ceftriaxone-resistantVancomycin 15 mg/kg IV q8–12h** plus ceftriaxone 2 g IV q12h
H. influenzaeAmpicillin-susceptibleAmpicillin 2 g IV q4h7 days
Ampicillin-resistantCeftriaxone 2 g IV q12h
N. meningitidisPenicillin-susceptiblePenicillin G 4 million units IV q4h7 days
Penicillin-resistantCeftriaxone 2 g IV q12h
L. monocytogenesn/aAmpicillin 2 g IV q4h plus gentamicin 1.7 mg/kg IV q8h≥ 21 days
**To achieve trough level of 15–20 mg/L

Clinical pearls

Adjunctive dexamethasone:

  • Associated with decreased mortality and neurologic sequelae in S. pneumoniae and H. influenzae → continue dexamethasone for four days
  • Shows no proven benefit in N. meningitidis and increased mortality in L. monocytogenes → discontinue upon microbiological diagnosis

Infection control:

  • Chemoprophylaxis for close contacts and droplet isolation for the first 24 hours of therapy are indicated only for N. meningitidis and H. influenzae
Accordion Items
  1. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284.
  2. van de Beek D, Cabellos C, Dzupova O, et al.; ESCMID Study Group for Infections of the Brain (ESGIB). ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62.
  3. van Ettekoven CN, van de Beek D, Brouwer MC. Update on community-acquired bacterial meningitis: guidance and challenges. Clin Microbiol Infect. 2017;23(9):601-606.
  4. Alford MA, Karlowsky JA, Adam HJ, et al. Antimicrobial susceptibility testing of invasive isolates of Streptococcus pneumoniae from Canadian patients: the SAVE study, 2011-2020. J Antimicrob Chemother. 2023 May 3;78(Suppl 1):i8-i16.
  5. de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549-1556.
  6. van de Beek D, Farrar JJ, de Gans J, et al. Adjunctive dexamethasone in bacterial meningitis: a meta-analysis of individual patient data. Lancet Neurol. 2010;9(3):254-263.